Vascular smooth muscle cells (VSMCs) derived from cardiovascular progenitor cell (CVPC) lineage populate the tunica media of the aortic root. Understanding differentiation of VSMCs from CVPC will further our understanding of the molecular mechanisms contributing to aortic root aneurysms, and thus, facilitate the development of novel therapeutic agents to prevent this devastating complication. It is established that the yes-associated protein (YAP) and Hippo pathway is important for VSMC proliferation and phenotype switch. To determine the role of YAP in differentiation of VSMCs from CVPCs, we utilized the in vitro monolayer lineage specific differentiation method by differentiating human embryonic stem cells into CVPCs, and then, into VSMCs. We found that expression of YAP decreased during differentiation of VSMC from CVPCs. Overexpression of YAP attenuated expression of VSMC contractile markers and impaired VSMC function. Knockdown of YAP increased expression of contractile proteins during CVPC-VSMCs differentiation. Importantly, expression of YAP decreased transcription of myocardin during this process. Overexpression of YAP in PAC1 SMC cell line inhibited luciferase activity of myocardin proximal promoter in a dose dependent and NKX2.5 dependent manners. YAP protein interacted with NKX2.5 protein and inhibited binding of NKX2.5 to the 5 0 -proximal promoter region of myocardin in CVPC-derived VSMCs. In conclusion, YAP negatively regulates differentiation of VSMCs from CVPCs by decreasing transcription of myocardin in a NKX2.5-dependent manner. STEM CELLS 2017;35:351-361 
INTRODUCTION
Aortic aneurysms are associated with aortic dissection and rupture, which are lethal. There is no medical treatment to prevent or reverse aortic aneurysm. Aortic aneurysms could develop from the loss of vascular smooth muscle cells (VSMCs) in the media layer of the aortic wall, leading to progressive aortic dilation. Sixty percent of aortic aneurysms involve the aortic root [1] . Specifically, the subgroup of VSMCs located in the media layer of aortic root is differentiated from second heart fieldderived cardiovascular progenitor cells (CVPCs), thereby playing a critical role in the pathological progression of aortic root aneurysms [2] . There is a need to further elucidate the mechanisms in CVPC-derived VSMC differentiation so that novel therapeutic strategies can be developed to prevent aortic root aneurysm.
Yes-associated protein (YAP) is a key cotranscription factor involved in the Hippo signaling that includes upstream kinases (NF2, MST1/2, LATS1/2), major cotranscription factors (YAP/TAZ), and transcription factors TEAD1-4 [3] . Our group, as well as evidence from other groups, found that Yap was a central regulator of the VSMC phenotype switch and neointima formation after artery injury in adult rodent models [4, 5] . Neural crest-specific deletion of Yap and Taz [6, 7] caused deficiency of neural crest development and subsequent VSMC differentiation. Conditional deletion of Yap with a Sm22a-Cre in mice showed that knockout of Yap was sufficient to impede VSMC proliferation resulting in vessel wall thinning and vascular morphological defects [8] . These studies suggest that YAP plays an important role in VSMC repair and vascular development. However, it is unknown how YAP regulates the process of VSMCs differentiation from cardiovascular progenitor cell lineage.
The development of human embryonic and induced pluripotent stem cells [9, 10] has provided new sources to sizably derive VSMCs and offers valuable advantages for identifying novel factors in controlling VSMCs-lineage differentiation. As a newly developed humanized in vitro tool, in vitro monolayer VSMC differentiation demonstrated advantages in differentiation lineage, origin, and stage controlling [11, 12] . Importantly, differentiated VSMCs exhibited transcription and metabolomics profile similar to primary VSMCs [13] . Therefore, in vitro lineage and stage controlled human VSMC differentiation models can facilitate ways to dissect the modulators and pathways involved in different lineages and stages. It also can be utilized to improve quality of tissue engineered vascular grafts for future patient treatment. [14, 15] In this study, we adopted the in vitro monolayer VSMC differentiation system by differentiating human embryonic stem cells (hESCs) H1 cell line into VSMCs through cardiovascular progenitor cells (CVPCs) lineage [12, 15] . Since myocardin is the most potent driver for VSMC differentiation [16] [17] [18] [19] and YAP has been showed to abolish myocardin's function majorly by protein-protein interaction [4] , we hypothesized that YAP would inhibit the differentiation of CVPCs to VSMCs by inhibiting the function of myocardin.
MATERIALS AND METHODS

Cell Culture and VSMC Differentiation
Human embryonic stem cell line H1 was cultured monolayer by using TeSR-E8 feeder free culture medium (STEMCELL Technologies, Vancouver, Canada, www.stemcell.com). VSMC differentiation protocol from H1 ESCs was modified from published papers and our previous report [12, 15] . As VSMC differentiation from CVPC stage was our research interest, it is illustrated in Figure 1A . [4, 20] and cultured in 5% fetal bovine serum (Sigma). Primary VSMCs were treated with identical VSMC differentiation medium for 2 days before being compared to CVPC-VSMCs.
RNA Extraction, Reverse Transcription and Real-Time Quantitative Polymerase-Chain Reaction
Total RNA from cultured cells was extracted with the RNeasy Plus Micro and Mini kit (Qiagen, Germantown, MD, www. qiagen.com), and cDNA was synthesized with the Superscript IV first-strand synthesis system (Invitrogen, Carlsbad, CA, www. thermofisher.com). Quantitative realtime PCR amplification was carried out using custom primers with iTaq SYBR supermix (Bio-Rad, Laboratories, Hercules, CA, www.bio-rad.com) as described in our previous reports [15] . The housekeeping gene GAPDH was served as internal control.
Western Blot Analysis, Immunofluorescence Staining, and Flow Cytometry
Western blot analysis was carried out as we described previously [4] . Whole cell lysate samples were prepared using the RIPA buffer (Thermo Fisher Scientific) supplemented with a protease inhibitor mixture (Roche Applied Science, Indianapolis, IN, www.lifescience.roche.com). Antibodies against GAPDH (1:1,000, Santa Cruz, Santa Cruz, CA, http:// www.scbt.com/), smooth muscle a-actin (SM a-actin) (1:1,000, sigma), Smooth muscle Myosin heavy chain 11(SMMHC) (1:500, Abcam, Cambridge, MA, www.abcam. com), SM22a (1:1000; Abcam), calponin1 (1:1,000, Sigma), YAP (1:1,000, Cell signal technology, Danvers, MA, www. cellsignal.com), and NKX2.5 (1:200, Santa Cruz) were used to examine individual protein expression. Immuno-activity and band density were visualized by the Odyssey system (LI-COR Biosciences) according to the manufacturer's instructions.
Immunofluorescence staining was performed according to a method described previously [15] were infected twice with above viruses at day1 and day 2 of VSMC differentiation (Fig. 1A) , and then infected cells were differentiated with VSMC differentiation medium for another three days before analysis. Overexpression of YAP in PAC1 cell line was also achieved with lentivirus pLX304-YAP and pLX304 as controls.
Carbachol and Angiotensin II Contractility Assays
Differentiated VSMCs were stimulated with 100 mM Carbachol (Sigma) or 10 mM angiotensin II (MP Biomedicals, Santa Ana, CA, www.mpbio.com). To test the specificity of angiotensin II induced contraction was through angiotensin II type 1 receptor, VSMCs were pretreated with inhibitor losartan (10 mM, Sigma) for 1 hour and then stimulated with 10 mM angiotensin II (MP Biomedicals). The contractions of cells were recorded with Nikon microscope and changes of cell surface area after 30 minutes were analyzed using ImageJ software.
Luciferase Activity Assay
Rat smooth muscle cell line PAC1 cells (generous gift from Dr. Li Li, Wayne State University) were seeded in 24-well plates for 24 hours. The cells then were transiently transfected by Lipofectamine 2000 (Invitrogen) with pGL3-MYOCD promoterluciferase reporter (MYOCD WT) or the mutated promoter reporter without NKX2.5-binding element (MYOCD NKE mut) [23] (generous gift from Dr. Shiyou Chen, The University of Georgia). Thymidine kinase Renilla luciferase reporter vector was used for dual-luciferase assay. pcDNA-YAP plasmid was transfected for YAP overexpression in PAC-1. Forty-eight hours post-transfection, cells were lysed, and luciferase activity was detected with the Dual-Luciferase reporter assay system (Promega, Madison, WI, www.promega.com). The activity of thymidine kinase Renilla served as an internal standard.
Chromatin Immunoprecipitation Assay (ChIP)
Chromatin immunoprecipitation assay (ChIP) assays were performed in both PAC1 and CVPC-derived VSMCs by using EZChIP kit (EMD Millipore, Calbiochem, Billerica, MA, www. emdmillipore.com) according to manufacturer's manual. Chromatin complexes from YAP lentivirus infected cells were immunoprecipitated with 1 mg of Nkx2.5 antibody or IgG (negative control). Quantitative realtime PCR were performed to amplify the Myocd promoter region containing Nkx2.5-binding element (NKE) using the following primer set: for PAC1 SMC cell line: 5-TTCCGCCTCCTCTCTGATTC-3 (forward) and 5-CCTTTTCCTCCTCCTCTGGG-3 (reverse); for CVPC-VSMCs: 5-TCAGGTGATTCTCCCACCTC-3 (forward) and 5-TCACACCTGT AATCCCAGCA-3 (reverse).
Coimmunoprecipitation (Co-IP)
For HEK293 cells, pcDNA-YAP-Myc (Addgene) and pcDNANkx2.5 (generous gift from Dr. Shiyou Chen, The University of Georgia) were cotransfected into HEK293 cells, and cells were harvested 48 hours post-transfection. For the process of CVPC-VSMCs differentiation, seeded CVPCs were infected with pLX304-YAP or pLX304-Vector virus at day1 and day 2, and cells were harvested 3 days later. The coimmunoprecipitation (Co-IP) assay was performed as described in a previous report [24] . Briefly, cells were lysed in lysis buffer (50 mM Tris-HCl, pH 7.8, 137 mM NaCl, 1 mM EDTA, 0.1% Triton X-100 with a protease inhibitor mixture). After centrifugation at 12,000 rpm for 10 minute at 48C, the supernatants were collected and pre-cleared with protein A/G plus-agarose for 1 hour at 48C. Anti-Myc-Tag (Cell signal technology) or anti-YAP (Cell signaling technology) antibodies were added into precleared supernatants and incubated overnight at 48C. Normal IgG was used for a negative control. The protein complex was pulled down by incubation of A/G plus-agarose for 1 hour at 48C and washed three times with wash buffer (0.2 mM EDTA, 100 mM KCl, 2 mM Mgcl 2 , 0.1% Tween-20, and 10% glycerol). The immunoprecipitants were analyzed by Western Blotting.
Immuno-activity and band density were visualized by the Odyssey system (LI-COR Biosciences) according to the manufacturer's instructions.
RESULTS
Characterization of VSMCs Differentiated from ESCs Derived CVPCs: Highly Efficient and Comparable with Primary Human VSMCs
We previously established a method involving highly specific induction of CVPCs from human embryonic stem cells [12, 15] . In this study, we were able to further differentiate VSMCs through induced CVPCs by treatment with TGF-b only. The differentiation of VSMCs using TGF-b only was as good as that using TGF-b and PDGF-BB (Fig. 1A , Supporting Information Fig. S1A ). Flow cytometry analysis showed approximately 90% of differentiated VSMCs were positive by staining with the anti-human smooth muscle heavy chain 11 (SMMHC) antibody, which is the most specific differentiation marker for smooth muscle maturation (Fig. 1B) . The efficiency was consistent to the differentiation efficiency by using other SMC markers as we previously reported [15] . Furthermore, CVPC-VSMCs and the primary VSMCs shared a comparable mRNA expression level of VSMC contractile markers including ACTA2, TAGLN, and MYH11, and all the contractile markers were higher than primary aortic fibroblast (Fig. 1C) . Primary VSMCs and CVPC-VSMCs showed similar and typical VSMC cell morphology and contractile fiber structure by immunofluorescent staining. Similar expression levels of contractile proteins including smooth muscle a-actin (SM aactin), calponin, SM22a, and smooth muscle heavy chain 11 (SMMHC) were detected between human primary VSMCs and CVPC-VSMCs by immunofluorescent staining (Fig. 1D) . To exclude the possibility of differentiation of CVPCs to cardiomyocytes and endothelial cells during the VSMC differentiation, we examined expression of MYH6, MYH7, CD31 and CD34 (Supporting Information Fig. S1B, S1C ). We found MYH7 was undetectable (data not shown) and other markers of cardiomyocytes and endothelial cells decreased during CVPC-VSMC differentiation.
Expression of YAP Decreased During VSMCs Differentiation from CVPCs
To determine role of YAP in VSMC differentiation, mRNAs transcription patterns of VSMCs markers and Hippo signaling were profiled during the VSMC differentiation from CVPCs. As shown in Figure 2A (CVPCs) to day 7 (mature VSMCs), while expression of YAP, TAZ, and TEAD4 decreased (Fig. 2B, Supporting Information  Fig. S2 ). Moreover, expression of upstream kinase LATS2 and NF2 increased with no change in TEAD1/2/3 (Supporting Information Fig. S2 ). These findings suggest that YAP's function was decreased during CVPC-VSMC differentiation. These findings were validated by Western blot (Fig. 2C ) and immunofluorescent analysis (Fig. 2D ). Taken together, we found a negative correlation between expression of YAP and myocardin/VSMC markers in CVPC-VSMC differentiation, indicating YAP was a negative regulator for VSMC differentiation from CVPCs. 
Overexpression of YAP Decreased Expression of VSMCs Markers and its Contractile Function, and Knockdown of YAP/TAZ Increased Expression of VSMC Markers
To further confirm YAP as a negative regulator for VSMC differentiation from CVPCs, the effect of YAP overexpression during VSMC differentiation from CVPCs was examined. As expected, overexpression of YAP significantly decreased mRNA and protein levels of multiple VSMC differentiation markers, including ACTA2, CNN, TAGLN, MYH11, and SMTNB (Fig. 3A,  3B ). With treatment of carbachol and angiotensin II, a significant decrease in contractile function was found in the YAP overexpressed VSMCs by quantifying the reduction of cell surface area (Fig. 3C, 3D ) (Supporting Information Videos S1-S4). Pretreating VSMCs with losartan abolished angiotensin II induced contraction in both YAP-overexpression and control groups, confirming a specific response of VSMCs to angiotensin II (Fig. 3D) . Based on the results that gain-of-function of YAP attenuated CVPCs-derived VSCMs differentiation, we further determined if loss-of-function of YAP would abolish its inhibitory effects on VSMCs differentiation from CVPCs. Given that YAP and TAZ behaved complementarily and overlapping [3] , knockdown of YAP and TAZ together was carried out with shRNA lentivirus. Compared to the scramble control group, expression of YAP and TAZ were significantly inhibited in shYAP and shTAZ VSMCs (Fig. 4A, 4B ). For VSMC markers, knockdown of YAP and TAZ resulted in a significant increase in expression of VSMC contractile markers by both RT-qPCR and Western blot (Fig. 4A, 4B ). Western blot was repeated three times and relative expression level compared to GAPDH of each protein was quantified (Fig. 4C) .
YAP Inhibited Myocardin Transcription by Preventing NKX2.5 Binding to Myocardin Promoter
To further examine how YAP regulates the differentiation of VSMCs, we analyzed the expression of myocardin, the master regulator of VSMC differentiation. We found that expression of myocardin in differentiated VSMCs was down-regulated in YAP overexpressed group (Fig. 5A ) and upregulated in YAP and TAZ knockdown group (Fig. 5B ) compared to the control groups. To identify the potential cis-elements located in myocardin promoter that was involved in YAP-mediated inhibition, we compared YAP effects on both luciferase activities of wild type myocardin promoter and its mutant (illustrated in Fig.  5C ) in PAC1 rat SMC cell line. First, we examined the activities of luciferase reporters driven by the wild type 1.9 kb 5 0 -proximal upstream DNA fragments in the myocardin gene. By cotransfecting the wild type myocardin promoter luciferase plasmid and pcDNA-YAP construct, we found that YAP inhibited luciferase activity of the myocardin promoter in a dosedependent manner compared to the pcDNA vector control group (Fig. 5D) . Transcription factor NKX2.5 was demonstrated to be an activator for myocardin expression both in cardiomyocytes [25] and SMCs [23, 26] and a NKX2.5 binding element (NKE) was conserved in the myocardin promoter. Myocardin promoter luciferase plasmid with mutated NKX2.5 binding element was cotransfected with pcDNA-YAP construct. Results showed that YAP-mediated inhibitory effects were abolished in the NKE-mutated myocardin promoter luciferase reporter group (Fig. 5E) , indicating YAP inhibited the transcription of myocardin through NKX2.5. We also performed Chip-PCR on PAC1 SMC cells between YAP overexpression group and vector control group to explore the effects of YAP on NKX2.5's binding to endogenous myocardin promoter. We found that YAP overexpression significantly attenuated NKX2.5's binding to the endogenous myocardin promoter (Fig. 5F ). To explore the possibility that protein-protein interaction between YAP and NKX2.5 may contribute to YAP-mediated inhibitory effects on myocardin expression, we overexpressed YAP-Myc and NKX2.5 in HEK 293 cells and performed immunoprecipatation with an anti-Myc antibody. Immunoblotting on NKX2.5 demonstrated that YAP-NKX2.5 protein physically interacted with each other (Fig. 5G) , which indicated that YAP was able to bind with NKX2.5 and interfere NKX2.5's transcription activation on myocardin.
YAP Interfered with NKX2.5 Protein During CVPC-VSMC Differentiation and Attenuated VSMC Differentiation in a NKX2.5 Dependent Manner Consistent with results from PAC1 cells, we found that overexpression of YAP inhibited NKX2.5's binding to the myocardin promoter during CVPC-VSMC differentiation (Fig. 6A, 6B) . Moreover, knockdown of NKX2.5 decreased expression of myocardin and VSMC markers, which was validated by two shNKX2.5 constructs (Fig. 6C) . Based on our finding, we hypothesized that during CVPC-VSMC differentiation, knockdown of NKX2.5 could block the positive effects of YAP and TAZ knockdown on VSMC marker expression. As expected, further knockdown of NKX2.5 in YAP/TAZ knockdown cells showed (Fig. 6D, Supporting Information Fig. S3 ) decreased expression of myocardin and VSMC markers compared to the YAP and TAZ knockdown only group. These results indicated that YAP attenuates VSMC differentiation, at least in part, in a NKX2.5 dependent manner.
DISCUSSION
In this study, we examined the function of YAP in the CVPCVSMCs differentiation process and underlying mechanism. Our results showed that expression of YAP decreased when CVPCs were differentiated into VSMCs (Fig. 2 ). Overexpression and knockdown of YAP demonstrated that YAP inhibited the expression of contractile proteins and contractile function of CVPC-derived VSMCs (Figs. 3 and 4) . Finally, we found that YAP decreased transcription of myocardin by interfering with NKX2.5's binding to the 5 0 -proximal promoter region of myocardin gene.
To our knowledge, this was the first study to identify that YAP inhibited the expression of VSMCs contractile markers through NKX2.5 during the differentiation process from CVPCs. Our finding is consistent with preclinical data showing forced expression of Yap in rodent matured SMCs downregulated the expression of SMCs markers and promoted synthetic phenotypic switch [4, 5, 27] . However, different from our finding that knockdown of YAP and TAZ increased expression of myocardin and VSMC markers, significant increases of VSMC markers were not found in the Sm22a-Cre Yap deletion mice [8] . The possible reason for this difference includes increased Taz expression in Yap deletion mice may have compensated for the lack of Yap. As a matter of fact, this compensatory increase of Taz has been previously reported by FinchEdmondson et al., when Yap was knocked out [28] .
Previous studies indicate that Yap1 [4] and TEAD1 proteins [29] were able to interfere with the function of myocardin and abolish its activation of smooth muscle cell contractile markers through protein-protein interaction. Similarly, our results showed YAP negatively regulated function of myocardin and YAP attenuated function of myocardin by inhibiting transcription of myocardin in a dose and NKX2.5 dependent manner. As indicated herein, Nkx2.5 was an activator of myocardin transcription and important in the maturation of VSMCs, which is consistent with previous findings [23, 26] . Importantly, we found that protein-protein interaction between YAP and NKX2.5 mediated YAP's inhibition on myocardin transcription and myocardin-driven VSMC differentiation. YAP is characterized with one or two WW domains (two splicing variants, YAP1 and YAP2, respectively) [30] . The WW domain is a protein-protein interaction module, which prefers to bind to ligands containing proline-rich sequences. Interestingly, a proline-rich sequence is conserved in human, rat, and mouse NKX2.5 proteins. It is quite likely that the motifs in YAP discussed above contribute to the binding to NKX2.5. Future studies are warranted to identify the specific protein domain responsible for binding between YAP and NKX2.5.
Besides regulating VSMCs differentiation, YAP also played an important role in VSMC-progenitor cells development. Recent studies showed that neural crest-specific deletion of Yap and Taz with Wnt1-Cre or WntCre 2SOR [6, 7] abrogated Notch signaling and caused severe neural tube vessel regression. Differentiation of VSMC from neural crest was interfered and resulted in aortic arch aneurysm and hemorrhaging. Moreover, a Tead2 binding element in the myocardin distal promoter has also been identified in early cardiovascular development [31] , suggesting that the YapTead complex may be important during the progenitor stage of VSMC differentiation. We also found that expression of YAP and TAZ increased when H1 ESCs differentiated into CVPCs (data not shown), indicating that YAP functions variably during distinct differentiation stages. Taken together, YAP is very important in the development of the vascular system and YAP's function may vary during different developmental stages. For aortic aneurysm development, besides the findings in rodent models [6] [7] [8] , it was suggested that YAP may be a potential target for development of human ascending aortic aneurysms [32] . However, future studies with a larger human sample cohort are needed to identify the role of YAP in both aortic root and ascending aortic aneurysm development.
CONCLUSION
In conclusion, by using the in vitro ESC-CVPC-VSMCs monolayer differentiation model, our study demonstrated a negative regulation of YAP in the CVPC-VSMC differentiation process. We found YAP blocked NKX2.5's binding to myocardin promoter and inhibited transcription of myocardin during this process (Fig. 7) . We identified novel modulators in VSMC differentiation and provided a potential target for understanding the development of aortic root aneurysm. 
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